Detailed Information

Cited 2 time in webofscience Cited 2 time in scopus
Metadata Downloads

A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/ NIRVANA-R trial

Authors
Park, JunsikLim, Myong CheolLee, Jae-KwanJeong, Dae HoonKim, Se IkChoi, Min ChulKim, Byoung-GieLee, Jung-Yun
Issue Date
Mar-2022
Publisher
대한부인종양학회
Keywords
Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Bevacizumab; Retreatment; Recurrence
Citation
Journal of Gynecologic Oncology, v.33, no.2
Indexed
SCIE
SCOPUS
KCI
Journal Title
Journal of Gynecologic Oncology
Volume
33
Number
2
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/55524
DOI
10.3802/jgo.2022.33.e12
ISSN
2005-0380
Abstract
Background Given the expanding clinical use of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPis), there is a significant need for optimal strategies with which to treat patients whose cancer progresses while using a PARPi. However, the treatment consensus after PARPi has not been established. The aim of the Korean Gynecologic Oncology Group (KGOG) 3056/NIRVANA-R trial is to investigate the efficacy of niraparib in combination with bevacizumab as a maintenance therapy in platinum-sensitive ovarian cancer patients who were previously treated with a PARPi. Methods The KGOG 3056/NIRVANA-R is a multi-centre, investigator-initiated, single-arm, phase II trial of patients with platinum-sensitive recurrent ovarian cancer recruited from seven KGOG sites. This study included patients with platinum-sensitive recurrent epithelial ovarian cancer who received at least 2 previous courses of platinum-containing therapy and had been treated with a PARPi. Mucinous histology type was excluded. Patients who had responded to the last platinum regimen (either complete or partial response) were eligible to participate in this study. Forty-four patients will be recruited. All enrolled patients are treated with niraparib and bevacizumab for maintenance therapy until disease progression, unacceptable toxicity, or withdrawal of patient consent. The primary endpoint of the study is 6-month progression-free survival rate. Accrual is expected to be completed in 2022, followed by presentation of results in 2023. Trial Registration ClinicalTrials.gov Identifier: NCT04734665
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Obstetrics and Gynecology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Lee, Jae Kwan photo

Lee, Jae Kwan
Guro Hospital (Department of Obstetrics and Gynecology, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE